Safety check: cuvitru under the microscope for immune deficiency patients

NCT ID NCT06565078

Recruiting now Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study looks back at medical records of about 100 people in Japan with primary immunodeficiency who received Cuvitru. The goal is to track serious side effects like allergic reactions, blood clots, and meningitis. No new treatment is given—researchers are simply analyzing existing data to better understand the drug's safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cuvitru (immune globulin subcutaneous, human, 20% solution)
What this could lead to: If successful, this study could confirm that Cuvitru is safe for people with primary immunodeficiency, supporting its continued use.
What could go wrong: This is a retrospective database review, not a controlled trial, so it cannot prove cause and effect. Results may not apply outside Japan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PID) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inborn error of immunity Primary Immunodeficiency Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IMMUNODEFICIENCY DISEASES (PID)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Takeda selected site
RECRUITING

Tokyo, Tokyo, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.